Treatment options

The goals of treatment in patients with HF are to improve their clinical status, functional capacity and quality of life, prevent hospital admission and reduce mortality. Neuro-hormonal antagonists (ACEIs, MRAs and beta-blockers) have been shown to improve survival in patients with HFrEF and are recommended for the treatment of every patient with HFrEF, unless contraindicated or not tolerated. A new compound (sacubitril/valsartan) that combines the moieties of an ARB (valsartan) and a neprilysin(NEP) inhibitor (sacubitril) has been shown to be superior to an ACEI (enalapril) in reducing the risk of death and of hospitalization for HF. Sacubitril/valsartan is therefore recommended to replace ACEIs in ambulatory HFrEF patients who remain symptomatic despite optimal therapy.1,2

 

Guidelines for diagnosis and treatment of acute and chronic heart failure
Discover the guidelines here

 

  1. Ponikowski P, et al. Eur Heart J. 2016;37:2129-2200.
  2. McMurray JJ. N EnglJ Med 2014;371:993–1004.
BE2307053199

Événements d'cardiologie

BSC 2023

09.02.2023

Discover the 2023 congress’ highlights from our Belgian experts

SEE DETAILS

ESC-HFA 202

20.05.2023

Discover the 2023 congress’ highlights

SEE DETAILS

CX Talks

09.05.2023

Peer-to-peer online meeting concept where young cardiologists share their Cardio Xperience on actual topics, that go beyond the hospital

SEE DETAILS

 

voir tous les événements d'cardiologie »

 

×

Ask the speakers